Shandong Xinhua Pharmaceutical Company Limited Class H (0719) Stock Statistics & Valuation Metrics

Shandong Xinhua Pharmaceutical Company Limited Class H has a market cap or net worth of HK$9.90B. The enterprise value is HK$5.41B.

Shandong Xinhua Pharmaceutical Company Limited Class H has 195,000,000 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shandong Xinhua Pharmaceutical Company Limited Class H’s return on equity (ROE) is 0.09 and return on invested capital (ROIC) is 7.16%.

The current PE Ratio of Shandong Xinhua Pharmaceutical Company Limited Class H is 10.6. Shandong Xinhua Pharmaceutical Company Limited Class H’s PEG ratio is -1.90.

In the last 12 months, Shandong Xinhua Pharmaceutical Company Limited Class H had revenue of 8.47B and earned 470.02M in profits. Earnings per share was 0.69.

In the last 12 months, operating cash flow was 234.13M and capital expenditures -76.81M, giving a free cash flow of 207.96M billion.

Shandong Xinhua Pharmaceutical Company Limited Class H pays an annual dividend of HK$0.273, resulting in a dividend yield of 4.2%

Shandong Xinhua Pharmaceutical Company Limited Class H upcoming earnings date is Oct 23, 2025, TBA (Confirmed).

Shandong Xinhua Pharmaceutical Company Limited Class H as a current ratio of 1.33, with Debt / Equity ratio of 14.53%

In the past 12 months, Shandong Xinhua Pharmaceutical Company Limited Class H has paid 46.94M in taxes.

Shandong Xinhua Pharmaceutical Company Limited Class H EV to EBITDA ratio is 3.44, with an EV/FCF ratio of 24.69.

Shandong Xinhua Pharmaceutical Company Limited Class H has HK$1.28B in cash and marketable securities with HK$744.68M in debt, giving a net cash position of HK$530.33M billion.

Gross margin is 21.34%, with operating margin of 6.31%, and net profit margin of 5.55%.

The average price target for Shandong Xinhua Pharmaceutical Company Limited Class H is ―, which is 11.43% higher than the current price. The consensus rating is ―